Evidence map›Paper›PMID 35415355›Full record

ArticleACS omega2022

Shengzhi Liu, Zhuoheng Zhong, Zijian Sun, Jingkui Tian, Kaisa Sulaiman, Eman Shawky, Hongwei Fu, Wei Zhu

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Shengzhi LiuCollege of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang 310027, China.
Zhuoheng ZhongCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Zijian SunCollege of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang 310027, China.
Jingkui TianThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310002, China.
Kaisa SulaimanThe Xinjiang Uygur Autonomous Region National Institute of Traditional Chinese Medicine, Urumchi, Xinjiang 830092, China.
Eman ShawkyDepartment of Pharmacognosy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.ORCID https://orcid.org/0000-0003-0089-9629
Hongwei FuCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Wei ZhuThe Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310002, China.ORCID https://orcid.org/0000-0001-9582-3787
Zhejiang Cancer Hospital · CNZhejiang Sci-Tech University · CNZhejiang University · CNAlexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moracins, a kind of 2-phenyl-benzofuran compound from Moraceae, serve as phytoalexins with antimicrobial, anti-inflammatory, antitumor, and antidiabetes activities and respond to biotic and abiotic stresses, while their biosynthetic pathway and regulatory mechanism remain unclear. Here, we report a

Identifiers

PMID35415355
PMCPMC8992258
OpenAlexW4223434439

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.